BPMC
Blueprint Medicines Corp. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website blueprintmedicines.com
- Employees(FY) 661
- ISIN US09627Y1091
Performance
+1.08%
1W
-2.31%
1M
+16.5%
3M
+23.93%
6M
+14.43%
YTD
+79.63%
1Y
Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: BPMC
Overview
In this investment analysis report, we will delve into a comprehensive evaluation of BPMC, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash fl...
Technical Analysis of BPMC 2024-05-31
Overview:
In analyzing the technical indicators for BPMC over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...
Recent News & Updates
- 2024-05-01 20:36
- 2024-05-01 20:10
- 2024-05-01 19:00
- 2024-04-30 10:00
- 2024-04-25 10:01
- 2024-04-24 22:01
- 2024-04-18 08:00
- 2024-04-17 20:00
- 2024-04-11 08:00
- 2024-04-10 20:00
- 2024-04-04 16:01
- 2024-04-04 04:01
- 2024-03-29 07:17
- 2024-03-28 08:13
Insiders Are Dumping These 10 Healthcare Stocks(Insider Monkey)
- 2024-03-27 20:13
Insiders Are Dumping These 10 Healthcare Stocks(Insidermonkey)
- 2024-03-22 11:30
- 2024-03-21 11:30
- 2024-03-17 08:50
30 Biggest Biotechnology Companies in the World(Insider Monkey)
- 2024-03-16 20:50
30 Biggest Biotechnology Companies in the World(Insidermonkey)
- 2024-03-15 19:00
- 2024-03-12 08:03
- 2024-03-06 16:01
- 2024-03-06 11:53
Q4 2023 Rigel Pharmaceuticals Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-03-06 03:01
- 2024-02-23 08:00
- 2024-02-22 19:00
- 2024-02-17 07:36
Blueprint Medicines Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-02-16 15:30
- 2024-02-16 09:37
- 2024-02-16 05:47